Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FGFR2 M538I |
| Gene Variant Detail | |
| Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FGFR2 M538I | Advanced Solid Tumor | decreased response | FGFR Inhibitor (Pan) | Dovitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597). | 23908597 |
| FGFR2 M538I | Advanced Solid Tumor | decreased response | PD173074 | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597). | 23908597 | |
| FGFR2 M538I | Advanced Solid Tumor | decreased response | FGFR Inhibitor (Pan) | Ponatinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597). | 23908597 |
| FGFR2 M538I | breast cancer | sensitive | FGFR Inhibitor (Pan) | FIIN-3 + Fulvestrant | Preclinical - Cell culture | Actionable | In a preclinical study, Faslodex (fulvestrant) and FIIN-3 combination treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 M538I in culture (PMID: 32723837). | 32723837 |
| FGFR2 M538I | estrogen-receptor positive breast cancer | sensitive | FGFR2 Inhibitor | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Fexagratinib (AZD4547) treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 M538I in culture (PMID: 32723837). | 32723837 |
| FGFR2 M538I | estrogen-receptor positive breast cancer | sensitive | FGFR Inhibitor (Pan) | FIIN-2 | Preclinical - Cell culture | Actionable | In a preclinical study, FIIN-2 treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 M538I in culture (PMID: 32723837). | 32723837 |
| FGFR2 M538I | estrogen-receptor positive breast cancer | sensitive | FGFR Inhibitor (Pan) | FIIN-3 | Preclinical - Cell culture | Actionable | In a preclinical study, FIIN-3 treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 M538I in culture (PMID: 32723837). | 32723837 |
| FGFR2 M538I | estrogen-receptor positive breast cancer | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 M538I in culture (PMID: 32723837). | 32723837 | |
| FGFR2 M538I | estrogen-receptor positive breast cancer | sensitive | SHP099 | Preclinical - Cell culture | Actionable | In a preclinical study, SHP099 treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 M538I in culture (PMID: 32723837). | 32723837 |